This is an index of side effect / adverse reaction reports (a.k.a. adverse event reports) related to Epirubicin and submitted to the FDA during the sample period of about a year. The information is not vetted and should not be considered as verified clinical evidence.
Reports by Event Outcome
All Cases (264)
Death (40)
Life Threatening Events (19)
Disability (14)
Reports by Reaction Type
Neutropenia (25),
Amenorrhoea (18),
Dyspnoea (17),
Febrile Neutropenia (16),
Pyrexia (15),
Nausea (12),
Vomiting (10),
Arthralgia (10),
Leukopenia (10),
Death (9),
Menopausal Symptoms (9),
Hot Flush (8)
Below are a few examples of reports where side effects / adverse reactions may be related to Epirubicin. For a complete list or a specific selection of reports, please use the links above.
Possible Epirubicin side effects in male
Reported by a physician from United Kingdom on 2012-08-23
Patient: male, weighing 82.0 kg (180.4 pounds)
Reactions: Coronary Artery Disease
Adverse event resulted in: death
Drug(s) suspected as cause:
Avastin
Dosage: most recent dose: 02/may/2012; most recent dose: 577 mg
Indication: Gastric Cancer
Start date: 2012-03-21
Cisplatin
Dosage: most recent dose: 02/may/2012; most recent dose: 110 mg
Indication: Gastric Cancer
Start date: 2012-03-21
Epirubicin
Dosage: most recent dose: 02/may/2012; most recent dose: 96 mg
Indication: Gastric Cancer
Start date: 2012-03-21
Xeloda
Dosage: most recent dose: 09/may/2012 and most recent dose: 2500 mg daily
Administration route: Oral
Indication: Gastric Cancer
Start date: 2012-03-21
Possible Epirubicin side effects in
Reported by a health professional (non-physician/pharmacist) from Italy on 2012-08-20
Patient:
Reactions: Abdominal Pain, Vomiting, Hypersensitivity, Nausea, Skin Toxicity, Mucosal Inflammation, Fatigue, Diarrhoea, Hepatotoxicity, Neutropenia
Adverse event resulted in: hospitalization
Drug(s) suspected as cause:
Cyclophosphamide
Indication: Breast Cancer
Epirubicin
Indication: Breast Cancer
Fluorouracil
Indication: Breast Cancer
Herceptin
Dosage: loading dose
Indication: Breast Cancer
Herceptin
Dosage: maintenance dose
Lapatinib
Dosage: arm b
Administration route: Oral
Indication: Breast Cancer
Lapatinib
Dosage: arm c
Administration route: Oral
Paclitaxel
Indication: Breast Cancer
Possible Epirubicin side effects in 73 year old male
Reported by a health professional (non-physician/pharmacist) from Korea, Republic of on 2012-08-16
Patient: 73 year old male
Reactions: Hepatitis C
Drug(s) suspected as cause:
Cisplatin
Dosage: 60 mg/m2, cyclic
Indication: Hepatic Neoplasm Malignant non-Resectable
Epirubicin
Dosage: 50 mg/m2, cyclic
Indication: Hepatic Neoplasm Malignant non-Resectable
Other drugs received by patient: Lipiodol
Possible Epirubicin side effects in 35 year old female
Reported by a physician from Philippines on 2012-08-16
Patient: 35 year old female, weighing 56.2 kg (123.6 pounds)
Reactions: Death
Adverse event resulted in: death
Drug(s) suspected as cause:
Cyclophosphamide
Dosage: form:vialtotal dose recieved:936 mg
Start date: 2010-11-04
Docetaxel
Dosage: form:vialtotal dose recieved:152 mg
Start date: 2010-09-02
Epirubicin
Dosage: form:vialtotal dose recieved:140 mg
Start date: 2010-11-04
Fluorouracil
Dosage: form:vial
Start date: 2010-11-04
Trastuzumab
Dosage: form:vialtotal dose recieved:336 mg
Start date: 2011-07-21
Trastuzumab
Dosage: form:vial
Possible Epirubicin side effects in 74 year old male
Reported by a health professional (non-physician/pharmacist) from Korea, Republic of on 2012-08-16
Patient: 74 year old male
Reactions: Hepatitis C
Drug(s) suspected as cause:
Cisplatin
Dosage: 60 mg/m2, cyclic
Indication: Hepatic Neoplasm Malignant non-Resectable
Epirubicin
Dosage: 50 mg/m2, cyclic
Indication: Hepatic Neoplasm Malignant non-Resectable
Other drugs received by patient: Lipiodol
Possible Epirubicin side effects in
Reported by a health professional (non-physician/pharmacist) from Japan on 2012-08-13
Patient:
Reactions: Dyspnoea, Brain Natriuretic Peptide Increased, Ejection Fraction Decreased, Nail Disorder, Cardiac Failure Congestive, Infusion Related Reaction
Drug(s) suspected as cause:
Adriamycin PFS
Dosage: 40-60 mg/m2 for fac and 60 mg/m2 for ac
Indication: Breast Cancer
Cyclophosphamide
Dosage: 500 mg/m2 for fac regimen and 600 mg/m2 for ac regimen
Indication: Breast Cancer
Docetaxel
Indication: Breast Cancer
Doxorubicin Hydrochloride
Dosage: 40-60 mg/m2 for fac and 60 mg/m2 for ac
Indication: Breast Cancer
Epirubicin
Dosage: 75-100 mg/m2
Indication: Breast Cancer
Fluorouracil
Indication: Breast Cancer
Paclitaxel
Indication: Breast Cancer
Trastuzumab
Dosage: 8 mg/kg followed by maintenance (md) 6 mg/kg every 3 wks or 4 mg/kg followed by 2 mg/kg weekly md
Indication: Breast Cancer
Possible Epirubicin side effects in female
Reported by a health professional (non-physician/pharmacist) from France on 2012-08-13
Patient: female
Reactions: Oesophageal Candidiasis
Drug(s) suspected as cause:
Cyclophosphamide
Start date: 2011-10-14
End date: 2011-10-14
Cyclophosphamide
Start date: 2011-09-16
Cyclophosphamide
Start date: 2011-09-02
Cyclophosphamide
Start date: 2011-09-30
Epirubicin
Start date: 2011-09-16
Epirubicin
Start date: 2011-09-30
Epirubicin
Start date: 2011-09-02
Epirubicin
Start date: 2011-10-14
End date: 2011-10-14
Other drugs received by patient: Neupogen; Taxol; Tamoxifen Citrate; Docetaxel; Acetaminophen and Codeine Phosphate; Docetaxel; Acetaminophen and Codeine Phosphate
Possible Epirubicin side effects in
Reported by a consumer/non-health professional from Japan on 2012-08-10
Patient:
Reactions: Injection Site Vasculitis, Injection Site Pain, Injection Site Phlebitis
Drug(s) suspected as cause:
Epirubicin
Indication: Breast Cancer
Fosaprepitant Dimeglumine
Dosage: 150 mg, once
Indication: Prophylaxis of Nausea and Vomiting
Start date: 2012-02-06
End date: 2012-02-06
Fosaprepitant Dimeglumine
Dosage: 150 mg, once
Start date: 2012-02-27
End date: 2012-02-27
Fosaprepitant Dimeglumine
Dosage: 150 mg, once
Start date: 2012-03-19
End date: 2012-03-19
Other drugs received by patient: Cyclophosphamide
Possible Epirubicin side effects in 74 year old male
Reported by a health professional (non-physician/pharmacist) from Korea, Republic of on 2012-08-09
Patient: 74 year old male
Reactions: Hepatitis C
Drug(s) suspected as cause:
Cisplatin
Dosage: 60 mg/m2
Indication: Hepatic Neoplasm Malignant non-Resectable
Epirubicin
Dosage: 50 mg/m2
Indication: Hepatic Neoplasm Malignant non-Resectable
Other drugs received by patient: Lipiodol
Possible Epirubicin side effects in 73 year old male
Reported by a health professional (non-physician/pharmacist) from Korea, Republic of on 2012-08-09
Patient: 73 year old male
Reactions: Hepatitis C
Drug(s) suspected as cause:
Cisplatin
Dosage: 60 mg/m2
Indication: Hepatic Neoplasm Malignant non-Resectable
Epirubicin
Dosage: 50 mg/m2
Indication: Hepatic Neoplasm Malignant non-Resectable
Other drugs received by patient: Lipiodol
Possible Epirubicin side effects in
Reported by a health professional (non-physician/pharmacist) from Japan on 2012-08-09
Patient:
Reactions: Brain Natriuretic Peptide Increased, Dyspnoea, Ejection Fraction Decreased, Nail Disorder, Cardiac Failure Congestive, Infusion Related Reaction
Drug(s) suspected as cause:
Cyclophosphamide
Dosage: 500 mg/m2 for fac regimen and 600 mg/m2 for ac regimen
Indication: Breast Cancer
Docetaxel
Indication: Breast Cancer
Doxorubicin Hydrochloride
Dosage: 40-60 mg/m2 for fac and 60 mg/m2 for ac
Indication: Breast Cancer
Epirubicin
Dosage: 75-100 mg/m2
Indication: Breast Cancer
Fluorouracil
Indication: Breast Cancer
Paclitaxel
Indication: Breast Cancer
Trastuzumab
Dosage: 8 mg/kg followed by maintenance (md) 6 mg/kg every 3 wks or 4 mg/kg followed by 2 mg/kg weekly md
Indication: Breast Cancer
Possible Epirubicin side effects in 35 year old female
Reported by a physician from Philippines on 2012-08-09
Patient: 35 year old female, weighing 56.2 kg (123.6 pounds)
Reactions: Death
Adverse event resulted in: death
Drug(s) suspected as cause:
Cyclophosphamide
Dosage: form:vialtotal dose recieved:936 mg
Start date: 2010-11-04
Docetaxel
Dosage: form:vialtotal dose recieved:152 mg
Start date: 2010-09-02
Epirubicin
Dosage: form:vialtotal dose recieved:140 mg
Start date: 2010-11-04
Fluorouracil
Dosage: form:vial
Start date: 2010-11-04
Trastuzumab
Dosage: form:vial
Trastuzumab
Dosage: form:vialtotal dose recieved:336 mg
Start date: 2011-07-21
Possible Epirubicin side effects in female
Reported by a physician from Netherlands on 2012-07-30
Patient: female, weighing 61.5 kg (135.3 pounds)
Reactions: Febrile Neutropenia
Adverse event resulted in: hospitalization
Drug(s) suspected as cause:
Cyclophosphamide
Dosage: 885 mg, unk
Indication: Breast Cancer
Start date: 2011-03-22
Epirubicin
Dosage: 177 mg, unk
Indication: Breast Cancer
Start date: 2011-03-22
Fluorouracil
Dosage: 885 mg, unk
Indication: Breast Cancer
Start date: 2011-03-22
NO Treatment Received
Dosage: no treatment received
Indication: Breast Cancer
Other drugs received by patient: Granisetron
Possible Epirubicin side effects in
Reported by a consumer/non-health professional from Canada on 2012-07-30
Patient:
Reactions: Disease Progression
Drug(s) suspected as cause:
Cyclophosphamide
Indication: Product Used FOR Unknown Indication
Epirubicin
Indication: Product Used FOR Unknown Indication
Fluorouracil
Indication: Product Used FOR Unknown Indication
Xeloda
Indication: Product Used FOR Unknown Indication
Possible Epirubicin side effects in 57 year old female
Reported by a consumer/non-health professional from Spain on 2012-07-27
Patient: 57 year old female
Reactions: Pyrexia, Neutropenia, Hidradenitis, Infection
Adverse event resulted in: hospitalization
Drug(s) suspected as cause:
Docetaxel
Indication: Breast Cancer
Start date: 2006-08-23
End date: 2006-11-02
Epirubicin
Indication: Breast Cancer
Start date: 2006-08-23
End date: 2006-11-02
Other drugs received by patient: Hipoartel; Simvastatin; Ceftazidime; Pantoprazole
Possible Epirubicin side effects in 58 year old female
Reported by a physician from Taiwan, Province of China on 2012-07-24
Patient: 58 year old female, weighing 57.3 kg (126.1 pounds)
Reactions: Multi-Organ Failure, Pneumonia, Coagulopathy, Central Nervous System Lesion, Acute Respiratory Distress Syndrome, Neutropenia, Acute Respiratory Failure, Renal Failure Acute
Adverse event resulted in: death, life threatening event, hospitalization
Drug(s) suspected as cause:
Epirubicin
Start date: 2010-12-28
End date: 2010-12-28
Epirubicin
Indication: Breast Cancer
Start date: 2010-09-30
End date: 2010-09-30
Taxotere
Indication: Breast Cancer
Start date: 2010-09-30
End date: 2010-09-30
Taxotere
Start date: 2010-12-28
End date: 2010-12-28
Other drugs received by patient: Granocyte
Possible Epirubicin side effects in male
Reported by a physician from Poland on 2012-07-24
Patient: male, weighing 77.0 kg (169.4 pounds)
Reactions: Dyspnoea, Pleural Effusion, Palmar-Plantar Erythrodysaesthesia Syndrome, General Physical Health Deterioration, Neutropenia, Polyneuropathy, Disease Progression
Adverse event resulted in: death
Drug(s) suspected as cause:
Capecitabine
Indication: Metastatic Gastric Cancer
Start date: 2010-10-27
End date: 2011-04-06
Epirubicin
Indication: Metastatic Gastric Cancer
Start date: 2010-10-27
End date: 2011-04-06
Oxaliplatin
Indication: Metastatic Gastric Cancer
Start date: 2010-10-27
End date: 2011-04-06
Possible Epirubicin side effects in 65 year old female
Reported by a health professional (non-physician/pharmacist) from Taiwan, Province of China on 2012-07-23
Patient: 65 year old female, weighing 51.8 kg (114.0 pounds)
Reactions: Acinetobacter Infection, Postoperative Wound Infection, Postoperative Wound Complication, Wound Infection Staphylococcal
Adverse event resulted in: hospitalization
Drug(s) suspected as cause:
Cyclophosphamide
Dosage: df, every three weeks intravenous, df, every three weeks intravenous
Start date: 2010-08-07
Cyclophosphamide
Dosage: df, every three weeks intravenous, df, every three weeks intravenous
Start date: 2010-09-09
Epirubicin
Dosage: df, every three weeks intravenous, df, every three weeks intravenous
Indication: Breast Cancer
Start date: 2010-09-09
Epirubicin
Dosage: df, every three weeks intravenous, df, every three weeks intravenous
Indication: Breast Cancer
Start date: 2010-08-07
End date: 2010-08-07
Fluorouracil
Dosage: df, every three weeks intravenous, df, every three weeks intravenous
Indication: Breast Cancer
Start date: 2010-08-07
End date: 2010-08-07
Fluorouracil
Dosage: df, every three weeks intravenous, df, every three weeks intravenous
Indication: Breast Cancer
Start date: 2010-09-09
Other drugs received by patient: Granisetron; Dexamethasone; Lamivudine; Metoclopramide Hydrochloride
Possible Epirubicin side effects in female
Reported by a health professional (non-physician/pharmacist) from Thailand on 2012-07-23
Patient: female
Reactions: Febrile Neutropenia
Adverse event resulted in: hospitalization
Drug(s) suspected as cause:
Cyclophosphamide
Dosage: every cycle intravenous, every cycle intravenous, every cycle intravenous
Indication: Breast Cancer
Start date: 2011-01-05
End date: 2011-01-05
Cyclophosphamide
Dosage: every cycle intravenous, every cycle intravenous, every cycle intravenous
Indication: Breast Cancer
Start date: 2011-02-16
End date: 2011-02-16
Cyclophosphamide
Dosage: every cycle intravenous, every cycle intravenous, every cycle intravenous
Indication: Breast Cancer
Start date: 2010-12-08
End date: 2010-12-08
Epirubicin
Dosage: every cycle intravenous, every cycle intravenous, every cycle intravenous
Indication: Breast Cancer
Start date: 2011-02-16
End date: 2011-02-16
Epirubicin
Dosage: every cycle intravenous, every cycle intravenous, every cycle intravenous
Indication: Breast Cancer
Start date: 2010-12-08
End date: 2010-12-08
Epirubicin
Dosage: every cycle intravenous, every cycle intravenous, every cycle intravenous
Indication: Breast Cancer
Start date: 2011-01-05
End date: 2011-01-05
Fluorouracil
Dosage: every cycle intravenous, every cycle intravenous, every cycle intravenous
Indication: Breast Cancer
Start date: 2011-01-05
End date: 2011-01-05
Fluorouracil
Dosage: every cycle intravenous, every cycle intravenous, every cycle intravenous
Indication: Breast Cancer
Start date: 2011-02-16
End date: 2011-02-16
Fluorouracil
Dosage: every cycle intravenous, every cycle intravenous, every cycle intravenous
Indication: Breast Cancer
Start date: 2010-12-08
End date: 2010-12-08
Other drugs received by patient: Dexamethasone; Ondansetron
Possible Epirubicin side effects in 48 year old female
Reported by a health professional (non-physician/pharmacist) from Hong Kong on 2012-07-23
Patient: 48 year old female
Reactions: Vomiting, Nausea, Febrile Neutropenia, Oropharyngeal Pain
Adverse event resulted in: life threatening event, hospitalization
Drug(s) suspected as cause:
Cyclophosphamide
Dosage: 830mg, every cycle; 800mg, every cycle
Indication: non-Small Cell Lung Cancer
Start date: 2010-10-27
Cyclophosphamide
Dosage: 830mg, every cycle; 800mg, every cycle
Indication: non-Small Cell Lung Cancer
Start date: 2010-10-06
End date: 2010-10-06
Epirubicin
Dosage: 166mg every cycle; 140mg, every cycle
Indication: non-Small Cell Lung Cancer
Start date: 2010-10-06
End date: 2010-10-06
Epirubicin
Dosage: 166mg every cycle; 140mg, every cycle
Indication: non-Small Cell Lung Cancer
Start date: 2010-10-27
Fluorouracil
Dosage: 830 mg every cycle; 700 mg, every cycle
Indication: Breast Cancer
Start date: 2010-10-06
Fluorouracil
Dosage: 830 mg every cycle; 700 mg, every cycle
Indication: Breast Cancer
Start date: 2010-10-27
Possible Epirubicin side effects in female
Reported by a health professional (non-physician/pharmacist) from Thailand on 2012-07-23
Patient: female
Reactions: Diarrhoea, Chills, Febrile Neutropenia, Headache
Adverse event resulted in: hospitalization
Drug(s) suspected as cause:
Cyclophosphamide
Dosage: every cycle
Indication: Breast Cancer
Start date: 2010-12-08
End date: 2011-01-05
Epirubicin
Dosage: every cycle
Indication: Breast Cancer
Start date: 2010-12-08
End date: 2011-01-05
Fluorouracil
Dosage: every cycle
Indication: Breast Cancer
Start date: 2010-12-08
End date: 2011-01-05
Other drugs received by patient: Dexamethasone; Onsia
Possible Epirubicin side effects in female
Reported by a health professional (non-physician/pharmacist) from Thailand on 2012-07-23
Patient: female, weighing 61.2 kg (134.6 pounds)
Reactions: Febrile Neutropenia
Adverse event resulted in: hospitalization
Drug(s) suspected as cause:
Cyclophosphamide
Dosage: see image
Indication: Breast Cancer
Start date: 2009-12-02
End date: 2009-12-02
Cyclophosphamide
Dosage: see image
Indication: Breast Cancer
Start date: 2009-12-30
Epirubicin
Dosage: see image
Indication: Breast Cancer
Start date: 2009-12-30
Epirubicin
Dosage: see image
Indication: Breast Cancer
Start date: 2009-12-02
End date: 2009-12-02
Fluorouracil
Dosage: see image
Indication: Breast Cancer
Start date: 2009-12-02
End date: 2009-12-02
Fluorouracil
Dosage: see image
Indication: Breast Cancer
Start date: 2009-12-30
Possible Epirubicin side effects in 63 year old female
Reported by a health professional (non-physician/pharmacist) from Hong Kong on 2012-07-20
Patient: 63 year old female
Reactions: Febrile Neutropenia
Adverse event resulted in: life threatening event, hospitalization
Drug(s) suspected as cause:
Cyclophosphamide
Dosage: (df; every cycle), (df; dose reduced)
Indication: Breast Cancer
Start date: 2010-06-30
End date: 2010-06-30
Epirubicin
Dosage: (df; every cycle), (df; dose reduced)
Indication: Breast Cancer
Start date: 2010-06-30
End date: 2010-06-30
Fluorouracil
Dosage: (df; every cycle), (df; dose reduced)
Indication: Breast Cancer
Start date: 2010-06-30
End date: 2010-06-30
Possible Epirubicin side effects in 58 year old female
Reported by a health professional (non-physician/pharmacist) from Hong Kong on 2012-07-20
Patient: 58 year old female
Reactions: Neutropenia
Adverse event resulted in: hospitalization
Drug(s) suspected as cause:
Cyclophosphamide
Dosage: (df; every three weeks intravenous drip), (df; dose reduced intravenous drip)
Indication: Breast Cancer
Start date: 2010-08-04
End date: 2010-08-04
Epirubicin
Dosage: (df; every three weeks intravenous drip), (df; dose reduced)
Indication: Breast Cancer
Start date: 2010-08-04
End date: 2010-08-04
Fluorouracil
Dosage: (df; every three weeks intravenous drip), (df; dose reduced)
Indication: Breast Cancer
Start date: 2010-08-04
End date: 2010-08-04
Possible Epirubicin side effects in 44 year old female
Reported by a health professional (non-physician/pharmacist) from Japan on 2012-07-20
Patient: 44 year old female, weighing 55.5 kg (122.1 pounds)
Reactions: Abdominal Pain, Intestinal Ischaemia, Colitis Ischaemic, White Blood Cell Count Decreased, Vomiting, Blood Creatine Phosphokinase Increased, Gastrointestinal Necrosis, Pyrexia, Multi-Organ Failure, Diarrhoea, GAS Gangrene, Heart Rate Increased, Bone Marrow Failure, Neutropenia, Clostridial Infection
Adverse event resulted in: death, hospitalization
Drug(s) suspected as cause:
Cyclophosphamide
Dosage: 7 cycles, total 4 courses
Indication: Breast Cancer
Start date: 2011-07-22
End date: 2011-09-22
Epirubicin
Dosage: 7 cycles, total 4 courses
Indication: Breast Cancer
Start date: 2011-07-22
End date: 2011-09-22
Taxotere
Dosage: 4 cycles, total 3 courses, dose taken once daily
Indication: Breast Cancer
Start date: 2011-10-14
End date: 2011-11-25
Other drugs received by patient: Leucon; Lorazepam; Decadron Phosphate; Lorazepam; Kytril; Prochlorperazine; Kytril; Cepharanthin; Decadron Phosphate; Marzulene S
Possible Epirubicin side effects in 62 year old female
Reported by a health professional (non-physician/pharmacist) from Hong Kong on 2012-07-20
Patient: 62 year old female
Reactions: Febrile Neutropenia
Adverse event resulted in: hospitalization
Drug(s) suspected as cause:
Cyclophosphamide
Dosage: (df), (df; dose reduced)
Indication: Breast Cancer
Start date: 2010-07-23
End date: 2010-07-23
Epirubicin
Dosage: (df), (df; dose reduced)
Indication: Breast Cancer
Start date: 2010-07-23
End date: 2010-07-23
Fluorouracil
Dosage: (df), (df; dose reduced)
Indication: Breast Cancer
Start date: 2010-07-23
End date: 2010-07-23
Possible Epirubicin side effects in 46 year old female
Reported by a health professional (non-physician/pharmacist) from Croatia (Local Name: Hrvatska) on 2012-07-20
Patient: 46 year old female, weighing 60.0 kg (132.0 pounds)
Reactions: Neutropenia, Thrombocytopenia, Leukopenia
Adverse event resulted in: life threatening event
Drug(s) suspected as cause:
Epirubicin
Start date: 2012-05-17
End date: 2012-05-18
Epirubicin
Start date: 2012-05-17
End date: 2012-05-18
Epirubicin
Start date: 2012-05-17
End date: 2012-05-18
Ifosfamide
Start date: 2012-05-17
End date: 2012-05-18
Mesna
Start date: 2012-05-17
End date: 2012-05-18
Possible Epirubicin side effects in female
Reported by a health professional (non-physician/pharmacist) from Thailand on 2012-07-20
Patient: female
Reactions: Febrile Neutropenia
Adverse event resulted in: hospitalization
Drug(s) suspected as cause:
Cyclophosphamide
Dosage: (800 mg; every cycle), (800 mg; every cycle)
Indication: Breast Cancer
Start date: 2009-10-29
End date: 2009-10-29
Cyclophosphamide
Dosage: (800 mg; every cycle), (800 mg; every cycle)
Indication: Breast Cancer
Start date: 2010-01-04
End date: 2010-01-04
Epirubicin
Dosage: (150 mg; every cycle), (150 mg; every cycle)
Indication: Breast Cancer
Start date: 2010-01-04
End date: 2010-01-04
Epirubicin
Dosage: (150 mg; every cycle), (150 mg; every cycle)
Indication: Breast Cancer
Start date: 2009-10-29
End date: 2009-10-29
Fluorouracil
Dosage: (800 mg; every cycle), (800 mg; every cycle)
Indication: Breast Cancer
Start date: 2010-01-04
End date: 2010-01-04
Fluorouracil
Dosage: (800 mg; every cycle), (800 mg; every cycle)
Indication: Breast Cancer
Start date: 2009-10-29
End date: 2009-10-29
Other drugs received by patient: Ondansetron; Lenograstim; Dexamethasone
Possible Epirubicin side effects in female
Reported by a health professional (non-physician/pharmacist) from France on 2012-07-09
Patient: female
Reactions: Drug Intolerance, Tongue Neoplasm Malignant Stage Unspecified
Adverse event resulted in: hospitalization
Drug(s) suspected as cause:
Cyclophosphamide
Indication: Breast Neoplasm
Start date: 2011-08-01
Cyclophosphamide
Dosage: 14 days on 21 days
Start date: 2011-02-01
End date: 2011-07-01
Cyclophosphamide
Start date: 2004-12-03
End date: 2005-02-02
Doxorubicin HCL
Dosage: 9 courses
Indication: Product Used FOR Unknown Indication
Start date: 2009-02-19
End date: 2009-11-05
Doxorubicin HCL
Dosage: 8 courses
Start date: 2007-11-27
End date: 2008-06-24
Epirubicin
Indication: Product Used FOR Unknown Indication
Start date: 2004-12-03
End date: 2005-02-02
Fluorouracil
Indication: Product Used FOR Unknown Indication
Start date: 2004-12-03
End date: 2005-02-02
Taxotere
Indication: Product Used FOR Unknown Indication
Start date: 2005-03-08
End date: 2005-04-19
Other drugs received by patient: Aromasin; Navoban; Xeloda; Faslodex; Estracyt; Femara; Arimidex; Navelbine
Possible Epirubicin side effects in 50 year old female
Reported by a health professional (non-physician/pharmacist) from Japan on 2012-07-02
Patient: 50 year old female
Reactions: Acute Myeloid Leukaemia
Adverse event resulted in: death
Drug(s) suspected as cause:
Cyclophosphamide
Dosage: received eight courses.
Docetaxel
Dosage: eight courses.
Epirubicin
Dosage: received eight courses.
Therapeutic Radiopharmaceuticals
Dosage: received 50 gy of irradiation to conserved breast and supraclavicular fossa
|